JESSICA SEMYONOVA: Open Payments
NPI 1053098103 · ANNISTON, AL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$367 in 18 payments from 11 companies in 2025. Trend: 2023 $50 · 2024 $262 · 2025 $367
Food & beverage: $367
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 4 | $85 |
| Biogen, Inc. | 3 | $62 |
| AstraZeneca Pharmaceuticals LP | 3 | $57 |
| Dexcom, Inc. | 1 | $28 |
| Otsuka America Pharmaceutical, Inc. | 1 | $27 |
| Lilly USA, LLC | 1 | $23 |
| Optinose US, Inc. | 1 | $19 |
| Bayer Healthcare Pharmaceuticals Inc. | 1 | $19 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $17 |
| Novo Nordisk Inc | 1 | $16 |
Products named: LEQEMBI, VRAYLAR, BREZTRI, Dexcom G6 Transmitter, REXULTI, UBRELVY, MOUNJARO, AIRSUPRA.
Industry payments across AL — which companies pay providers there.
